Download presentation
Presentation is loading. Please wait.
Published byAnjali Beamish Modified over 10 years ago
1
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Dr Kreshnik Hoti BPharm, MPS, AACPA, PhD Best Practice Pharmacy Dementia care
2
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J 2 Learning outcomes Develop and understanding on medications used in dementia Identify medications that can worsen cognition Develop an understanding on medication related monitoring needs and outcomes in patients with dementia Develop an understanding on pharmacists’ role in Dementia care
3
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J What is dementia? Latin word ‘demens’ Broad term Symptoms descriptive of a range of conditions Brain function impairment Language, memory, perception, personality and cognitive skills >65 years of age, likelihood doubles in 5 year intervals
4
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Definition (WHO) “a syndrome due to disease of the brain, usually of a chronic or progressive nature, in which there is disturbance of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. Consciousness is not clouded. The impairments of cognitive function are commonly accompanied, and occasionally preceded, by deterioration in emotional control, social behaviour, or motivation. This syndrome occurs in Alzheimer’s disease, in cerebrovascular disease, and in other conditions primarily or secondarily affecting the brain”
5
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Early signs Ability to learn and remember new information Difficulties with tasks which are familiar Progression More basic activities affected Higher mental function impairment progress over months to years
6
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Cognitive, psychiatric and behavioural symptoms memory problems communication difficulties confusion, wandering, getting lost personality changes and behaviour changes such as agitation, repetition, following depression, delusions, apathy and withdrawal
7
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Dementia – national figures Source: Alzheimer’s Australia 280.000 Australians 1600 new cases weekly 3 rd leading cause of death Worldwide cost: US$604 billion in 2010
8
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Source: Alzheimer’s disease international; World Alzheimer’s report 2010. The global economic impact of dementia
9
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Dementia major contributor to disability Source: World Health Organization. World Health Report 2003— Shaping the future. Geneva: WHO, 2003.
10
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Dementia predictions 35.6 million worldwide 4.6 million cases every year People affected double every 20 years 81.1 million people affected by 2040
11
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Dementia predictions cont’d Ferri et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–17
12
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Dementia – causes 62% (Alzheimer’s disease) 17% (vascular dementia) 10% (mixed dementia) 3% (other) 2% (fronto- temporal) 4% (lewy bodies)
13
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Dementia – causes Alzheimer’s disease causes: Biological Genetics Inflammation
14
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Risk factors Modifiable: Obesity Smoking Physical activity and exercise Alcohol Cognitive reserve *head injury
15
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Risk factors Treatable medical conditions: stroke diabetes midlife hypertension midlife hypercholesterolemia hyperhomocysteinaemia depression (?)
16
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Risk factors Non-Modifiable: age family history small head size male gender
17
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Treatment Patients and family involvement as soon as diagnosis is made Support for daily activities Address co-existing medical conditions Avoid medications exacerbating cognitive function Treat Vitamin B12 or folate deficiency if present
18
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Treatment No cure None of the available drugs prevent Alzheimer’s or modifies its pathology Symptoms such as memory loss and confusion may be reduced (for a limited time) Acetylcholinesterase inhibitors& memantine Combination
19
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Treatment - Acetylcholinesterase inhibitors Donepezil Galantamine Rivastigmine Decrease the breakdown of acetylcholine and therefore reduce the deficiency of cholinergic neurotransmitter activity First line agents
20
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Treatment - Acetylcholinesterase inhibitors 25-50% of patients experience delayed deterioration of cognition by 6 months 12-20% of patients by 1 year Benefits in cognition, function and global outcomes (MMSE gain 1.5-2 points) Benefits assessed after 3 months
21
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Acetylcholinesterase inhibitors-ADVERSE EFFECTS Incidence related to dose Use in some patients is limited by adverse effects, especially gastrointestinal Common: nausea, vomiting, loss of appetite, diarrhoea Commonly increase bladder and bowel urgency and contribute to incontinence
22
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Treatment - memantine AD associated with excess glutamate, therefore memantine reduces glutamate-induced neuronal degradation Specialist initiated Moderate to severe AD Benefits in cognition, function, global outcome Common adverse effects: Headache, constipation, confusion and dizziness
23
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Treatment summary GenericDosage formDoseApproved forContraindicated Donepezil (Aricept) tablet5mg up to 10mg evening All stagesGI/ureteric obstruction; Active PU Galantamine (Reminyl, Galantyl) CR capsule8mg daily up to 16mg morning with food Mild to moderateSevere hepatic impairment; CrCl <10 mL/minute; GI/ureteric obstruction; Active PU Rivastigmine (Exelon) Capsule, oral liquid, patch Oral: 1.5mg BD up to 6mg BD CC Patch: 4.5mg up to 9.5mg daily Mild to moderateSevere hepatic impairment; GI/ureteric obstruction; Active PU Memantine (Ebixa) Tablet5 mg up to 20mg daily Moderate to severe History of seizures
24
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Pharmaceutical Benefits Scheme implications Acetylcholinesterase inhibitors and memantine require authority approval Donepezil example: INITIAL APPLICATION FOR THE TREATMENT OF MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE - Patients with an (S)MMSE of 10 or more Confirmation of diagnosis must be made by or in consultation with a specialist/consultant physician (including a psychiatrist). To continue treatment: patient demonstrated improvement in cognitive function
25
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Vitamins and supplements Do they help? B vitamins Omega 3 Mediterranean diet Vitamin E Ginkgo Biloba Aspirin Brahmi
26
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Other agents Statins Testosterone Oestrogen Anti-inflammatory agents Selegiline Future therapies
27
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Medications negatively affecting dementia Drugs with anticholinergic effects (Australian Medicines Handbook 2012) amantadine, amitriptyline, atropine belladonna alkaloids, benzhexol, benztropine, biperiden, brompheniramine chlorpheniramine, chlorpromazine, clomipramine, clozapine, cyclizine, cyclopentolate, cyproheptadine darifenacin, dexchlorpheniramine, dimenhydrinate, diphenhydramine, disopyramide, dothiepin, doxepin glycopyrrolate homatropine, hyoscine (butylbromide or hydrobromide) imipramine, ipratropium (nebulised) mianserin nortriptyline olanzapine, orphenadrine, oxybutynin pericyazine, pheniramine, pizotifen, prochlorperazine, promethazine, propantheline solifenacin tiotropium, tolterodine, trimeprazine, trimipramine, triprolidine, tropicamide
28
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Medications negatively affecting dementia Anticholinergic Cognitive Burden (ACB) Score 1-3 Definite anticholinergics score 2&3 Every definite anticholinergic increases the risk of cognitive impairment by 46% over 6 years 1 point increase in ACB score = 0.33 decline in MMSE over 2 yrs Antipsychotics Sedatives Tricyclic antidepressants
29
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Behavioural and psychological symptoms in dementia (BPSD) Challenging & distressing Causes: Brain cells progressively deteriorate Environmental Medications
30
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J BPSD Early stages: irritability anxiety depression Later stages: aggression agitation emotional distress hallucinations outbursts delusion sleep disturbances restlessness
31
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J BPSD Review/Treat potential underlying causes: Possible physical causes of distress or delirium Pain, dehydration, LUTS, infection… Medications which impair cognition Environmental factors Depression
32
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J BPSD treatment Non-drug options – first line Antipsychotics (hallucinations, delusions or seriously disturbed behaviour) Mood stabilizers such as carbamazepine or valproate Antidepressants Acetylcholinesterase inhibitors or memantine Anxiety and agitation (oxazepam for no longer than 2 weeks)
33
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Antipsychotics – considerations: Risperidone approved for BPSD Recommended for use when symptoms cause severe distress or immediate risk of harm Monitor if behaviour improved and adverse effects tolerated Therapy reviewed every three months Many troublesome symptoms do not respond BPSD often resolves spontaneously within 12 weeks Antipsychotics increase the risk of death in BPSD patients
34
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Pharmacists’ role Refer patients with suspected cognitive impairment Early diagnosis Patient & family counselling and education Promotion of risk reduction strategies
35
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Pharmacists’ role Source of information Patient, Family, Health professionals Monitoring drug interactions Monitoring drug contraindications Monitor medication compliance
36
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J Pharmacists’ role Dose administration aids Medication reviews Medication usage reviews Home medication reviews Identifying medications contributing/exacerbating cognitive decline Quality use of medicines
37
Curtin University is a trademark of Curtin University of Technology CRICOS Provider Code 00301J References Australian Medicines Handbook 2012 eTherapeutic Guidelines, Neurology Alzheimer’s Australia; http://www.fightdementia.org.au Alzheimer’s Australia; http://www.fightdementia.org.au Alzheimer’s Association; www.alz.org Alzheimer’s Association; www.alz.org Ballard et al. Alzheimer’s disease. Lancet 2011; 377: 1019–31 Ferri et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–17 Alzheimer’s disease international; World Alzheimer’s report 2010. The global economic impact of dementia World Health Organization. World Health Report 2003—Shaping the future. Geneva: WHO, 2003. McCullagh CD et al. Risk factors for dementia. Advances in Psychiatric Treatment 2001; 7:24–31 Australian Institute of Health and Welfare 2007. Dementia in Australia. National data analysis and development Archer et al. The effects of commonly prescribed drugs in patients with Alzheimer’s disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 2007;78:233–239. The Aging Brain Program at the IU Center for Aging Research. Anticholinergic Cognitive Burden List (ACB). 4/4/12 Campbell N, Boustani M, Limbil T, Ott C, et al. The cognitive impact of anticholinergics: a clinical review. Clinical Interventions in Aging. 2009;4(1):225-33
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.